can glp 1 cause insulin resistance GLP-1a: Going beyond Traditional Use GLP-1: Actions on Beta-cell Mass

A massive study of veterans suggests these medications may quiet cravings far beyond food.

Weight loss is known to trigger compensatory biology: Increased appetite signaling Reduced resting energy expenditure Heightened food reward sensitivity Stopping GLP-1 therapy at peak dose, without tapering and without reinforcing lifestyle strategies at the exact moment hunger returns, does not allow lifestyle behaviors to take over. Emerging real-world data and obesity physiology suggest a different, more clinically relevant path: Gradual dose reduction rather than abrupt cessation Continued, structured dietary and exercise support Active monitoring during the high-risk post-cessation period We still need randomized trials designed specifically to test tapering and lifestyle-anchored maintenance strategies

In late June, Teva Pharmaceuticals launched the first generic GLP-1 (Glucagon-Like-Peptide-1) receptor agonist in the United States, known as Liraglutide injection (6 mg/mL).

Cold sores and canker sores arent the same

Marble Falls, Jan

Initiating GLP-1RAs therapy shortly after surgery may help prevent WR